These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12385012)

  • 1. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.
    Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M
    Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells.
    Okai M; Nieda M; Tazbirkova A; Horley D; Kikuchi A; Durrant S; Takahashi T; Boyd A; Abraham R; Yagita H; Juji T; Nicol A
    Vox Sang; 2002 Oct; 83(3):250-3. PubMed ID: 12366768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.
    van der Vliet HJ; Molling JW; von Blomberg BM; Kölgen W; Stam AG; de Gruijl TD; Mulder CJ; Janssen HL; Nishi N; van den Eertwegh AJ; Scheper RJ; van Nieuwkerk CJ
    Clin Immunol; 2005 Feb; 114(2):183-9. PubMed ID: 15639652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
    Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
    J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
    Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
    J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.
    Kawano T; Nakayama T; Kamada N; Kaneko Y; Harada M; Ogura N; Akutsu Y; Motohashi S; Iizasa T; Endo H; Fujisawa T; Shinkai H; Taniguchi M
    Cancer Res; 1999 Oct; 59(20):5102-5. PubMed ID: 10537282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.
    Molling JW; Kölgen W; van der Vliet HJ; Boomsma MF; Kruizenga H; Smorenburg CH; Molenkamp BG; Langendijk JA; Leemans CR; von Blomberg BM; Scheper RJ; van den Eertwegh AJ
    Int J Cancer; 2005 Aug; 116(1):87-93. PubMed ID: 15756674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
    Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
    Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy.
    Takahashi T; Haraguchi K; Chiba S; Yasukawa M; Shibata Y; Hirai H
    Br J Haematol; 2003 Jul; 122(2):231-9. PubMed ID: 12846891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
    Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.